Company news

Recursion Pharmaceuticals, Inc. news in 2025

Recursion Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

December 7, 2025

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

November 30, 2025

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

November 4, 2025

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

November 4, 2025

Recursion to Participate in Upcoming Investor Conferences

November 3, 2025

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

October 27, 2025

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 7, 2025

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

August 4, 2025

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

July 28, 2025

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

July 7, 2025

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

June 5, 2025

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

May 3, 2025

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

April 27, 2025

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

April 21, 2025

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

April 8, 2025

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

April 7, 2025

Recursion to Participate in Upcoming Investor Conference

March 31, 2025

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

March 17, 2025

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

February 27, 2025

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

February 23, 2025

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

February 4, 2025

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

January 6, 2025

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

January 5, 2025

Calls in 2025

Decks in 2025